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 We have previously reported that transforming growth factor (TGF)-beta in 2 
the cerebrospinal fluid (CSF) is involved in the mechanism underlying the regulation of 3 
spontaneous motor activity (SMA) by the central nervous system after exercise. 4 
However, it remained unclear what physiological condition triggers the activation of 5 
TGF-beta. We hypothesized that the shortage of energy derived from fatty acid (FA) 6 
oxidation observed in the early phase of exercise activated TGF-beta in the CSF. To test 7 
this hypothesis, we investigated whether mercaptoacetate (MA), an inhibitor of FA 8 
oxidation, could induce an activation of TGF-beta in the CSF and a decrease in SMA. 9 
Intraperitoneal (i.p.) administration of MA activated TGF-beta in CSF in rats and 10 
depressed SMA; 2-deoxyglucose, an inhibitor of carbohydrate oxidation, on the other 11 
hand, depressed SMA but failed to activate CSF TGF-beta. Intracisternal administration 12 
of anti-TGF-beta antibody abolished the depressive effect of MA on SMA. We also 13 
found that the depression of SMA and the activation of TGF-beta in the CSF by i.p. MA 14 
administration were eliminated by vagotomy. Our data suggest that TGF-beta in the 15 
CSF is activated by the inhibition of FA oxidation via the vagus nerve and that this 16 
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 4 
1. Introduction 1 
  We previously demonstrated that transforming growth factor (TGF)-beta in 2 
the cerebrospinal fluid (CSF) was activated after exercise and that intracisternal (i.c.) 3 
administration of TGF-beta decreased spontaneous motor activity (SMA) in rodents 4 
[20,42]. These results indicated that activated TGF-beta in the CSF was one of the 5 
components in the system responsible for SMA depression after exercise. However, it 6 
remained unclear what physiological condition leads to activation of TGF-beta in the 7 
CSF. 8 
 The fact that TGF-beta in the CSF is activated during moderate intensity 9 
exercise [20] allows us to assume that certain metabolic alterations observed in exercise 10 
trigger the activation of TGF-beta in the CSF. During the transition from a sedentary 11 
state to the early phase of exercise, several catabolic alterations occur [37] in response 12 
to a drastic increase in energy expenditure [21]. Therefore, we focused on energy 13 
metabolism in the early phase of exercise, which we regarded as that period from the 14 
commencement of exercise until the achievement of a metabolic equilibrium state at a 15 
particular exercise intensity, which usually seems to be 10-20 minutes [17,21]. The 16 
 5 
main energy supply resources in exercise are carbohydrate and fat [7,8]. Because of the 1 
immediate responsiveness of glycogenolysis to increased energy demand [8], 2 
carbohydrate oxidation can rapidly increase in the early phase of exercise [17,21]. Fatty 3 
acid (FA) oxidation, on the other hand, increases gradually [17], because the 4 
responsiveness of FA mobilization from fat depots depends on triacylglycerol lipolysis. 5 
Lipolytic activity in adipose tissues during exercise is mediated by the autonomic 6 
nervous system and hormones; additionally, the delivery of fatty acids from adipose 7 
tissue to working muscles is mediated by increased blood flow velocity, which is also 8 
regulated by the autonomic nervous system and hormones [2,15,19]. Energy production 9 
from FA oxidation in the early phase of exercise is thus relatively inadequate until FA 10 
mobilization reaches a sufficient extent. Indeed, intravenous lipid infusion can increase 11 
FA oxidation in the early phase of exercise [33]. In addition, especially in this phase of 12 
exercise, FA levels in the blood can decrease [12]. These observations suggest that the 13 
extent of FA mobilization in the early phase of exercise is insufficient for the capacity 14 
for FA oxidation, or that, in other words, a relative shortage of energy derived from FA 15 
oxidation occurs in this phase of exercise. In the normal physiological state, such a 16 
 6 
shortage is observed only in the early phase of exercise.  1 
 Based on the foregoing, we hypothesized that a relative decrease in FA 2 
oxidation can trigger the activation of TGF-beta in the CSF. Indeed, intracisternal 3 
administration of TGF-beta induces a decrease in SMA [20] and an increase in FA 4 
oxidation [42]. The role of TGF-beta in the CSF is therefore counter-regulatory in 5 
response to a relatively decreased FA oxidation level. To test our hypothesis, we 6 
investigated SMA and TGF-beta levels in CSF in rats after intraperitoneal (i.p) 7 
administration of mercaptoacetate (MA), an FA oxidation inhibitor [3]. Administration 8 
of MA can mimic the physiological condition observed as the relative shortage of 9 
energy derived from FA oxidation in the early phase of exercise. To compare the effect 10 
of inhibition of fatty acid oxidation with that of the inhibition of carbohydrate oxidation, 11 
we also analyzed activated CSF TGF-beta concentrations and SMA after i.p. 12 
administration of 2-deoxyglucose (2-DG), a carbohydrate oxidation inhibitor [41]. We 13 
found that both metabolic inhibitors decreased SMA in rats, although only MA, the FA 14 
oxidation inhibitor, activated TGF-beta in the CSF. We also demonstrated that 15 





2. Materials & Methods 1 
2.1 Animals 2 
 Seven-week-old male Sprague-Dawley rats (Oriental Bio Service, Kyoto, 3 
Japan) were used. All animals were maintained under controlled environmental 4 
conditions (22°C ± 0.5°C, 12-h light-dark cycle), and fed normal chow (MF, Oriental 5 
Yeast, Tokyo, Japan) and water ad libitum for at least 1 week prior to their use in 6 
experiments. All animals were treated humanely, as outlined in the National Research 7 
Council’s guide for the Care and Use of Laboratory Animals (Kyoto University Animal 8 
Care Committee, according to NIH #86-23, revised 1985). In addition, all procedures 9 
were approved by the Kyoto University Animal Care and Use Committee. All 10 
experiments were started 2 h after the onset of the dark cycle. 11 
 12 
2.2 Determination of spontaneous motor activity after administration of metabolic 13 
inhibitors  14 
 MA (Wako, Osaka, Japan) and 2-DG (Nakalai Tesque, Kyoto, Japan) were 15 
administered i.p. to rats. To determine appropriate experimental conditions, we tested 16 
 9 
200, 400, and 600-µmol/kg body weight (B.W.) doses of MA, and 200, 400, and 1 
600-mg/kg B.W. doses of 2-DG. Time-course changes in SMA were measured over 1, 2, 2 
and 3-h durations for both MA and 2-DG. We selected doses of 400 µmol/kg B.W. for 3 
MA and 400 mg/kg B.W. for 2-DG, and a 2-h duration for all subsequent experiments. 4 
MA causes decreased energy production from FA oxidation [28] by inhibiting acyl-CoA 5 
dehydrogenase activity [3]. 2-DG induces a decrease in glucose oxidation through the 6 
competitive inhibition of phosphohexose isomerase [41]. MA and 2-DG were dissolved 7 
in sterile saline (Otsuka Pharmaceutical, Tokyo, Japan), and the same volume of saline 8 
was administered i.p. to rats in a control group. The rats were then deprived of food.  9 
After 2 h, the rats were moved from their home cage to a test cage (25 ! 38 ! 17.5 cm). 10 
SMA was measured using an infrared ray sensor (Muromachi Kikai, Tokyo, Japan) as 11 
described previously [42]. 12 
 13 
2.3 CSF Collection and determination of the level of active TGF-beta in the CSF 14 
 MA (400 µmol/kg B.W.) and 2-DG (400 mg/kg B.W.) were i.p. administered 15 
under the conditions described above. Two hours after administration, rats were 16 
 10 
anesthetized by administration of urethane (i.p., 1.5 g/kg B.W.) and CSF was collected. 1 
CSF collection and TGF-beta level assay were as described previously [27]. Briefly, 2 
CSF was collected from the cisterna magna after puncturing the atlantooccipital 3 
membrane with a 26G needle fitted to the tip of a micropipette and centrifuged at 2000 4 
g at 4°C. The supernatant was then collected and stored at "70°C until TGF-beta assay. 5 
TGF-beta concentrations in CSF were determined with a bioassay using 6 
TGF-beta-responsive mink lung epithelial cells (TMLCs) constitutively transfected with 7 
a TGF-beta-responsive human plasminogen activator inhibitor-1 promoter-luciferase 8 
construct (kindly provided by Dr. M. Abe, Department of Nanomedicine, Tokyo 9 
Medical and Dental University, Tokyo, Japan, and Dr. D. Rifkin, Department of Cell 10 
Biology, NYU Medical Center, New York, NY, USA) [1]. All samples were diluted 11 
with Dulbecco’s modified Eagle’s medium (DMEM) containing 0.1% bovine serum 12 
albumin (BSA). TMLCs suspended in DMEM with 10% fetal bovine serum were 13 
seeded onto 96-well plates (10,000 cells/well) and allowed to attach for 6 h; thereafter, 14 
the medium was replaced with 100 µL of sample solution. After a further 16 h, 15 
luciferase activity was measured using a luciferase assay system (Promega, Ann Arbor, 16 
 11 
MI), according to the manufacturer’s instructions. Levels of active TGF-beta in CSF are 1 
expressed as relative luminescence units (RLU). The average RLU value in control 2 
groups was defined as 100%.  3 
 4 
2.4 Intracisternal administration of anti-TGF-beta antibody 5 
 Rats were anesthetized by i.p. injection of 1 mg/kg pentobarbital sodium 6 
(Dainippon Seiyaku, Osaka, Japan) and placed in a stereotaxic frame adapted for rat 7 
surgery. Subsequently, the skull was exposed and a hole drilled to insert a cannula 8 
(24G). Coordinates for placing the cannula in the cisterna magna were as follows: AP, 9 
!2.5; ML, 0.0; and DV, !7.9 from the lambda; angle, !32° posteriorly. Rats were 10 
allowed 1 week to recover, and only animals with body weights greater than before 11 
surgery were used. On the day of an experiment, 5 µg anti-TGF-beta or control 12 
preimmune antibodies (R&D Systems, Minneapolis, MN) dissolved in 10 µL artificial 13 
cerebrospinal fluid (a-CSF; 140 mM NaCl, 3.35 mM KCl, 1.2 mM Na2PO4, 0.3 mM 14 
NaH2PO4, and 0.10% fatty-acid-free BSA) were administered i.c. Immediately 15 
afterwards, MA (400 µmol/kg B.W.) or 2-DG (400 mg/kg B.W.) was i.p. administered. 16 
 12 
Saline was administered as a control. 1 
 2 
2.5 Vagotomy 3 
 After anesthetization with an i.p. injection of 1 mg/kg pentobarbital sodium, 4 
rats were vagotomized as described by Li and Anderson [24]. In brief, a 5-cm midline 5 
incision was made in the abdomen to expose the stomach and lower esophagus. 6 
Thereafter, the bilateral vagal trunks were exposed and cut. A similar procedure was 7 
carried out during sham surgery, except that the vagal trunks were not damaged. Rats 8 
were allowed 2 weeks to recover from surgery. Because vagotomy decreases food 9 
intake for 2 weeks [24], operations were judged successful in rats whose food intake 10 
decreased for at least 2 weeks. Rats that failed to regain pre-operation body weight were 11 
excluded from subsequent experiments. There was an interval of at least 1 week 12 
between each SMA experiment. Firstly, SMA was determined after the i.p. 13 
administration of saline, and then the effects of i.p. administration of MA (400 µmol/kg 14 
B.W.) and 2-DG (400 mg/kg B.W.) on SMA were determined. Finally, SMA was 15 
determined in the untreated state. This sequence of experiment was not randomized, but 16 
 13 
we confirmed the last administration of inhibitors did not affect the next basal counts of 1 
SMA after one-week interval. CSF was collected from freshly vagotomized rats after a 2 
2 week recovery period, as described above. 3 
 4 
2.6 Statistical analysis 5 
 All data are expressed as mean ± S.E.M. Data in Figures 1B, 1D, 2, and 5 6 
were analyzed using Student’s t test. Data in Figure 3A were analyzed using a two-way 7 
analysis of variance (ANOVA), and there was a significant interaction between i.c. and 8 
i.p. administration. The data were then analyzed using one-way ANOVA, followed by 9 
multiple comparison testing using a post-hoc Tukey's multiple comparison test. Data in 10 
Figure 3B were analyzed using a two-way ANOVA, and there was no significant 11 
interaction between i.c. and i.p. administration. The data were then analyzed using a 12 
Student’s t test in the same factor. Data in Figure 4 were analyzed using a one-way 13 
ANOVA, followed by multiple comparison testing using a post-hoc Tukey's multiple 14 
comparison test.  P values of 5% or less were considered statistically significant. Prism 15 
4 for Mac (GraphPad Software, CA, USA) was used for statistical analysis. 16 
17 
 14 
3. Results 1 
3.1 Effect of i.p. administration of MA and 2-DG on SMA 2 
 Firstly, we investigated whether the inhibition of FA oxidation depressed 3 
SMA similarly to exercise [20] or TGF-beta i.c. administration [20,42]. We carried out 4 
SMA measurements after inhibition of FA oxidation by MA i.p. administration. 5 
Time-course changes in SMA over 60 min, 2 h after i.p. administration of MA (400 6 
µmol/kg B.W.), are presented in Figure 1A. The cumulative SMA value in the MA 7 
group was significantly lower than that in the saline group (Fig. 1B, P = 0.0036). To 8 
compare the effect of MA with another metabolic inhibitor, we tested whether 2-DG 9 
alters SMA in rats. Time-course changes in SMA over 60 min, 2 h after i.p. 10 
administration of 2-DG (400 mg/kg B.W.), are presented in Figure 1C. The cumulative 11 
SMA value in the 2-DG group was significantly lower than that in the saline group (Fig. 12 
1D, P < 0.0001).  13 
 14 
3.2 Effect of i.p. administration of MA and 2-DG on CSF TGF-beta levels 15 
 To address whether these metabolic inhibitors activate TGF-beta in CSF, we 16 
 15 
next measured TGF-beta levels in CSF after MA or 2-DG administration. Two hours 1 
after i.p. administration, the TGF-beta level in the CSF of rats given MA (400 µmol/kg 2 
B.W.) was significantly higher than that in rats given saline (Fig. 2A, P = 0.0295). In 3 
contrast, there was no significant difference between TGF-beta levels in the CSF 2 h 4 
after i.p. administration in rats given 2-DG (400 mg/kg B.W.) and rats given saline (Fig. 5 
2B, P = 0.6153).  6 
 7 
3.3 Effect of i.c. administration of anti-TGF-beta antibody on SMA after i.p. 8 
administration of MA and 2-DG 9 
 To determine whether increased TGF-beta in the CSF is required for 10 
decreased SMA after administration of MA, we tested whether i.c. administered 11 
anti-TGF-beta antibody eliminated the effect of MA on SMA. Previously, we had 12 
demonstrated that i.c. anti-TGF-beta antibody administration completely abolished the 13 
physiological effect of TGF-beta in the CSF [18, 19]. There was a statistically 14 
significant interaction between i.c. anti-TGF-beta antibody administration and i.p. MA 15 
administration (Fig. 3A, P = 0.026). The cumulative SMA value over 60 min in the 16 
 16 
control group that received preimmune antibody was significantly lower than that in the 1 
group that had received the anti-TGF-beta antibody (Fig 3A, P < 0.05). There was no 2 
significant interaction, however, between i.c. anti-TGF-beta administration and i.p. 3 
2-DG administration (Fig. 3B, P = 0.2973). In both the preimmune and anti-TGF-beta 4 
antibody-treated groups, cumulative SMA values over 60 min were significantly lower 5 
than that in the i.p. saline group (Fig. 3B, preimmune antibody, P = 0.0339; 6 
anti-TGF-beta, P = 0.00234). 7 
 8 
3.4 Effect of vagotomy on SMA after i.p. administration of MA and 2-DG 9 
 To determine whether the vagus nerve is involved in the effect of MA on 10 
SMA, we tested whether vagotomy reverses the depression in SMA after i.p. MA 11 
administration. In vagotomized rats, there was no significant difference between 12 
cumulative SMA values in the i.p. MA and i.p. saline groups (Fig. 4A, P > 0.05).  SMA 13 
after the i.p. administration of 2-DG was significantly lower than that in the i.p. saline 14 
group (Fig. 4A, P < 0.01).  In sham-operated rats, respective cumulative SMA values 15 
for the MA and 2-DG groups were significantly lower than that of the saline group (Fig. 16 
 17 
4B, MA, P < 0.05; 2-DG, P < 0.0001w). In the sedentary state, the cumulative SMA 1 
values of vagotomized and sham operated rats were 11030 ± 758 and 15120 ± 381.5, 2 
respectively (P < 0.001 by Student’s t test).  3 
 4 
3.5 Effect of vagotomy on CSF TGF-beta levels after intraperitoneal administration of 5 
MA 6 
 Finally, we tested whether vagotomy reversed the increase in TGF-beta 7 
produced by i.p. MA administration. In vagotomized rats, there was no significant 8 
difference between CSF TGF-beta levels in the i.p. MA and i.p. saline groups (Fig. 5A, 9 
P = 0.371). In sham-operated rats, the TGF-beta level in the CSF was significantly 10 
higher in animals that had received i.p. MA than in those that had received saline (Fig. 11 
5B, P = 0.0467). In the untreated state, there was no significant difference between 12 
TGF-beta levels in the CSF of vagotomized and sham-operated rats (data not shown).  13 
14 
 18 
4. Discussion 1 
 In this study, we demonstrated that the FA oxidation inhibitor, MA, activated 2 
TGF-beta in the CSF via the vagus nerve. Decreased SMA after exercise might prevent 3 
further undesirable energy exhaustion in animals and allow restoration of energy stores. 4 
The brain collects peripheral metabolic information and coordinates animal behavior to 5 
maintain energy homeostasis [29,36]. Thus, the decrease in SMA after exercise may not 6 
only result from the exhaustion of energy stores and potential damage in peripheral 7 
tissues but might also reflect a process that is more actively regulated by the CNS. The 8 
entire mechanism by which SMA is decreased after exercise by the CNS is still poorly 9 
understood; however, our reports [14,20,21,42] together with the results obtained in this 10 
study highlight that TGF-beta in the CSF plays a crucial role in the mechanism 11 
underlying the regulation of behavior by the CNS after exercise. 12 
It has previously been unclear what physiological conditions trigger the 13 
activation of TGF-beta in the CSF during exercise. We focused on the unique metabolic 14 
alteration which is observed as a relative shortage of energy derived from FA oxidation 15 
in the early phase of exercise [12,33]. We then hypothesized that the shortage of energy 16 
 19 
derived from FA oxidation activated TGF-beta in the CSF. As expected, the inhibition 1 
of FA oxidation activated TGF-beta in the CSF (Fig. 2). To rule out of the possibility 2 
that the activation of TGF-beta in the CSF by inibition of FA oxidation is observed only 3 
in MA administration, we measured TGF-beta levels in the CSF after i.p. administration 4 
of etomoxir, another inhibitor of FA oxidation. Etomoxir also activated TGF-beta in the 5 
CSF (Supplement Figure 1). Additionally a decrease in locomotor activity by 6 
administration of etomoxir is already shown [16]. Therefore, the activation of TGF-beta 7 
in the CSF and the subsequent decrease in SMA surely result from the inihibtion of FA 8 
oxidation. The inhibition of carbohydrate oxidation, on the other hand, did not activate 9 
TGF-beta in the CSF (Fig 2). Taking into consideration that i.c. administration of 10 
TGF-beta increases FA oxidation [42], TGF-beta in the CSF is involved in a 11 
counter-regulatory system that responds to decreased FA oxidation. We showed that i.c. 12 
administration of anti-TGF-beta antibody prevented the depressive effect of i.p. 13 
administration of MA on SMA (Fig. 3). This indicates that the activation of TGF-beta in 14 
the CSF is required for the depression of SMA induced by inhibition of FA oxidation. 15 
Taken together, our data suggest that the physiological condition that activates 16 
 20 
TGF-beta in the CSF during exercise is likely the shortage of energy derived from FA 1 
oxidation observed in the early phase of exercise. 2 
 It has been reported that the increased food intake observed following MA 3 
administration [35] is eliminated by vagotomy [23]. MA inhibits acyl-CoA 4 
dehydrogenase in the liver [3], decreases membrane potential and induces 5 
depolarization in hepatocytes [6], and leads to increased afferent activity in the hepatic 6 
vagus branch [26]. These observations suggest that information concerning deficient 7 
production of energy from FA oxidation is transmitted to the brain via the vagus nerve. 8 
Vagotomy eliminated the depressive effect of i.p. administration of MA on SMA 9 
(Fig. 4A), but not that of 2-DG (Fig. 4B). Intraperitoneal MA administration to 10 
vagotomized rats did not activate TGF-beta in the CSF (Fig. 5A). We are unable to rule 11 
out the possibility that ablation of the effect of MA on SMA by vagotomy resulted from 12 
the intrinsic effects of the vagotomy itself, which also affected SMA in the sedentary 13 
state. However, SMA values (Fig. 4) did appear to be inversely correlated with the 14 
concentration of active TGF-beta in CSF (Fig. 5). These data strongly support the 15 
contention that the vagus nerve is important in the activation of TGF-beta induced by 16 
 21 
inhibition of FA oxidation. 1 
It is unclear how the liver detects changes in FA oxidation levels and 2 
transmits signals to the brain via the vagus nerve. Because either administration of fatty 3 
acid or inhibitors of fatty acid oxidation, but not glucose, alters plasma membrane 4 
potential in hepatic cells in vitro and vivo  [6,26,34], it is possible that efferent sensory 5 
neurons directly sense an alternation in fatty acid oxidation. A report that the neuronal 6 
sensing pathway of inhibition of FA oxidation is different from that of glucose 7 
oxidation [30] also supports this notion. Inhibition of FA oxidation leads to reduction in 8 
adenosine triphosphate (ATP)/ adenosine diphosphate (ADP) ratio in the liver [13,18], 9 
on the other hand, a single administration of 2-DG does not decrease ATP/ADP ratio in 10 
the liver [38]. Then it is another explanation that consequence of reduction in ATP/ADP 11 
ratio induced by inhibition of FA oxidation results in changes in hepatic plasma 12 
membrane potential, which might be transmitted to sensory neurons by yet-unidentified 13 
mechanisms. Further studies are necessary to elucidate how information concerning 14 
deficient FA oxidation is transmitted from the liver to the brain. 15 
Despite numerous in vitro studies and in vivo studies under pathogenic 16 
 22 
conditions having shown the mechanism underlying the activation of TGF-beta 1 
[5,9,22,44], to the best of our knowledge there is no clear understanding of the 2 
TGF-beta activation mechanism in the CSF of rodents under in vivo physiological 3 
conditions. TGF-beta is widely distributed in the brain [39], and is expressed by various 4 
cell types [5]. The TGF-beta receptor is also widely expressed in the brain [4]. 5 
Therefore, from an immunohistochemical point of view, the particular location within 6 
the brain where TGF-beta is activated and responsible for depressing SMA and 7 
enhancing FA oxidation cannot be determined. However, we previously demonstrated 8 
that i.c. TGF-beta administration activates hypothalamic noradrenergic neurons [14], 9 
which project from the vicinity of the nucleus of the solitary tract (NTS). This suggests 10 
that TGF-beta can affect the NTS. Visceral information is transmitted mainly to the 11 
NTS via the vagus nerve system [36,40]. Therefore, inhibition of FA oxidation may 12 
activate TGF-beta via the vagus nerve and the NTS. Intravenous administration of MA 13 
induced c-Fos expression in several region including, NTS, hypothalamus, lateral 14 
parabrachial nucleus (IPBN), and the central nucleus of amygdala (CNA). [31]. The 15 
lesion of NTS, IPBN and CNA abolish the MA-induces appetites feeding behavior. 16 
 23 
[10,30,32]. Additionally, the finding that MA-induced feeding behavior is abolished in 1 
decerebrate rats indictates that the projection from NTS to forebrain is important for the 2 
feeding behavior induced by the inhibition of FA oxidation [11]. These reports are 3 
consistent with our report that TGF-beta in the brain activates NTS-hypothalamus 4 
circuits [14]. Further studies are needed to elucidate the mechanism underlying the 5 
activation of TGF-beta in the NTS and the subsequent decrease in SMA. 6 
 In conclusion, we have demonstrated that i.p. administration of MA, which 7 
inhibits FA oxidation, induces decreased SMA in rats. This effect of MA administration 8 
is transmitted via the vagus nerve and mediated by TGF-beta in the CSF. Impaired FA 9 
oxidation has been reported to lead to decreased SMA [16]. In addition, carnitine is an 10 
essential substance for beta-oxidation of FA and a decrease in SMA observed in fasting 11 
carnitine-deficient mice [25] can be rescued by carnitine administration [43]. This 12 
report also suggests a relationship between a reduction in energy supplied by FA 13 
oxidation and a decrease in SMA. Taking other studies into consideration, inhibition of 14 
FA oxidation strongly appears to lead to down-regulation of locomotor activity via the 15 
liver-vagus nerve-brain system. Our data suggest that TGF-beta in the CSF plays a 16 
 24 




 We thank Ayumi Yamada, Miyaki Takashi, Kayo Mizuno, Ryo Kitaoka, Koji 2 





[1] Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB. An assay for 3 
transforming growth factor-beta using cells transfected with a plasminogen activator 4 
inhibitor-1 promoter-luciferase construct. Anal Biochem 1994; 216: 276-84 5 
[2] Bartness TJ, Bamshad M. Innervation of mammalian white adipose tissue: 6 
implications for the regulation of total body fat. Am J Physiol 1998; 275: R1399-411 7 
[3] Bauche F, Sabourault D, Giudicelli Y, Nordmann J, Nordmann R. Inhibition 8 
in vitro of acyl-CoA dehydrogenases by 2-mercaptoacetate in rat liver mitochondria. 9 
Biochem J 1983; 215: 457-64 10 
[4] Bottner M, Unsicker K, Suter-Crazzolara C. Expression of TGF-beta type II 11 
receptor mRNA in the CNS. Neuroreport 1996; 7: 2903-7 12 
[5] Bottner M, Krieglstein K, Unsicker K. The transforming growth factor-betas: 13 
structure, signaling, and roles in nervous system development and functions. J 14 
Neurochem 2000; 75: 2227-40 15 
[6] Boutellier S, Lutz TA, Volkert M, Scharrer E. 2-Mercaptoacetate, an inhibitor 16 
of fatty acid oxidation, decreases the membrane potential in rat liver in vivo. Am J 17 
Physiol 1999; 277: R301-5 18 
[7] Brooks GA, Mercier J. Balance of carbohydrate and lipid utilization during 19 
exercise: the "crossover" concept. J Appl Physiol 1994; 76: 2253-61 20 
[8] Brouns F, van der Vusse GJ. Utilization of lipids during exercise in human 21 
subjects: metabolic and dietary constraints. Br J Nutr 1998; 79: 117-28 22 
[9] Brown PD, Wakefield LM, Levinson AD, Sporn MB. Physicochemical 23 
activation of recombinant latent transforming growth factor-beta's 1, 2, and 3. Growth 24 
Factors 1990; 3: 35-43 25 
[10] Calingasan NY, Ritter S. Lateral parabrachial subnucleus lesions abolish 26 
feeding induced by mercaptoacetate but not by 2-deoxy-D-glucose. Am J Physiol 1993; 27 
265: R1168-78 28 
[11] Darling RA, Ritter S. 2-Deoxy-D-glucose, but not mercaptoacetate, increases 29 
food intake in decerebrate rats. Am J Physiol Regul Integr Comp Physiol 2009; 297: 30 
R382-6 31 
[12] Friedberg SJ, Sher PB, Bogdonoff MD, Estes EH, Jr. The Dynamics Of 32 
Plasma Free Fatty Acid Metabolism During Exercise. J Lipid Res 1963; 4: 34-8 33 
 27 
[13] Friedman MI, Harris RB, Ji H, Ramirez I, Tordoff MG. Fatty acid oxidation 1 
affects food intake by altering hepatic energy status. Am J Physiol 1999; 276: R1046-53 2 
[14] Fujikawa T, Matsumura S, Yamada H, Inoue K, Fushiki T. Transforming 3 
growth factor-beta in the brain enhances fat oxidation via noradrenergic neurons in the 4 
ventromedial and paraventricular hypothalamic nucleus. Brain Res 2007; 1173: 92-101 5 
[15] Hodgetts V, Coppack SW, Frayn KN, Hockaday TD. Factors controlling fat 6 
mobilization from human subcutaneous adipose tissue during exercise. J Appl Physiol 7 
1991; 71: 445-51 8 
[16] Hogberg H, Engblom L, Ekdahl A, Lidell V, Walum E, Alberts P. 9 
Temperature dependence of O2 consumption; opposite effects of leptin and etomoxir on 10 
respiratory quotient in mice. Obesity (Silver Spring) 2006; 14: 673-82 11 
[17] Holloway GP, Bezaire V, Heigenhauser GJ, Tandon NN, Glatz JF, Luiken 12 
JJB, 1996 #35}, Bonen A, Spriet LL. Mitochondrial long chain fatty acid oxidation, 13 
fatty acid translocase/CD36 content and carnitine palmitoyltransferase I activity in 14 
human skeletal muscle during aerobic exercise. J Physiol 2006; 571: 201-10 15 
[18] Horn CC, Ji H, Friedman MI. Etomoxir, a fatty acid oxidation inhibitor, 16 
increases food intake and reduces hepatic energy status in rats. Physiol Behav 2004; 81: 17 
157-62 18 
[19] Horowitz JF, Klein S. Lipid metabolism during endurance exercise. Am J 19 
Clin Nutr 2000; 72: 558S-63S 20 
[20] Inoue K, Yamazaki H, Manabe Y, Fukuda C, Hanai K, Fushiki T. 21 
Transforming growth factor-beta activated during exercise in brain depresses 22 
spontaneous motor activity of animals. Relevance To central fatigue. Brain Res 1999; 23 
846: 145-53 24 
[21] Ishikawa T, Mizunoya W, Shibakusa T, Inoue K, Fushiki T. Transforming 25 
growth factor-beta in the brain regulates fat metabolism during endurance exercise. Am 26 
J Physiol Endocrinol Metab 2006; 291: E1151-9 27 
[22] Kondou H, Mushiake S, Etani Y, Miyoshi Y, Michigami T, Ozono K. A 28 
blocking peptide for transforming growth factor-beta1 activation prevents hepatic 29 
fibrosis in vivo. J Hepatol 2003; 39: 742-8 30 
[23] Langhans W, Scharrer E. Evidence for a vagally mediated satiety signal 31 
derived from hepatic fatty acid oxidation. J Auton Nerv Syst 1987; 18: 13-8 32 
[24] Li ET, Anderson GH. A role for vagus nerve in regulation of protein and 33 
 28 
carbohydrate intake. Am J Physiol 1984; 247: E815-21 1 
[25] Li MX, Yoshida G, Horiuchi M, Kobayashi K, Saheki T. Prolonged effect of 2 
single carnitine administration on fasted carnitine-deficient JVS mice regarding their 3 
locomotor activity and energy expenditure. Biochim Biophys Acta 2006; 1761: 1191-9 4 
[26] Lutz TA, Diener M, Scharrer E. Intraportal mercaptoacetate infusion increases 5 
afferent activity in the common hepatic vagus branch of the rat. Am J Physiol 1997; 6 
273: R442-5 7 
[27] Matsumura S, Shibakusa T, Fujikawa T, Yamada H, Inoue K, Fushiki T. 8 
Increase in transforming growth factor-beta in the brain during infection is related to 9 
fever, not depression of spontaneous motor activity. Neuroscience 2007; 144: 1133-40 10 
[28] Matsumura S, Saitou K, Miyaki T, Yoneda T, Mizushige T, Eguchi A, 11 
Shibakusa T, Manabe Y, Tsuzuki S, Inoue K, Fushiki T. Mercaptoacetate inhibition of 12 
fatty acid beta-oxidation attenuates the oral acceptance of fat in BALB/c mice. Am J 13 
Physiol Regul Integr Comp Physiol 2008; 295: R82-91 14 
[29] Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central 15 
nervous system control of food intake and body weight. Nature 2006; 443: 289-95 16 
[30] Ritter S, Taylor JS. Vagal sensory neurons are required for lipoprivic but not 17 
glucoprivic feeding in rats. Am J Physiol 1990; 258: R1395-401 18 
[31] Ritter S, Dinh TT. 2-Mercaptoacetate and 2-deoxy-D-glucose induce Fos-like 19 
immunoreactivity in rat brain. Brain Res 1994; 641: 111-20 20 
[32] Ritter S, Hutton B. Mercaptoacetate-induced feeding is impaired by central 21 
nucleus of the amygdala lesions. Physiol Behav 1995; 58: 1215-20 22 
[33] Romijn JA, Coyle EF, Sidossis LS, Zhang XJ, Wolfe RR. Relationship 23 
between fatty acid delivery and fatty acid oxidation during strenuous exercise. J Appl 24 
Physiol 1995; 79: 1939-45 25 
[34] Rossi R, Geronimi M, Gloor P, Seebacher MC, Scharrer E. Hyperpolarization 26 
of the cell membrane of mouse hepatocytes by fatty acid oxidation. Physiol Behav 27 
1995; 57: 509-14 28 
[35] Scharrer E, Langhans W. Control of food intake by fatty acid oxidation. Am J 29 
Physiol 1986; 250: R1003-6 30 
[36] Schwartz MW, Woods SC, Porte D, Jr., Seeley RJ, Baskin DG. Central 31 
nervous system control of food intake. Nature 2000; 404: 661-71 32 
[37] Soya H, Mukai A, Deocaris CC, Ohiwa N, Chang H, Nishijima T, Fujikawa T, 33 
 29 
Togashi K, Saito T. Threshold-like pattern of neuronal activation in the hypothalamus 1 
during treadmill running: establishment of a minimum running stress (MRS) rat model. 2 
Neurosci Res 2007; 58: 341-8 3 
[38] Torlinska T, Rutkowska D, Hryniewiecki T, Paluszak J. In vivo effect of 4 
2-deoxy-D-glucose on adenine nucleotide levels in the liver and skeletal muscle of rats. 5 
Acta Physiol Pol 1990; 41: 76-84 6 
[39] Unsicker K, Flanders KC, Cissel DS, Lafyatis R, Sporn MB. Transforming 7 
growth factor beta isoforms in the adult rat central and peripheral nervous system. 8 
Neuroscience 1991; 44: 613-25 9 
[40] Uyama N, Geerts A, Reynaert H. Neural connections between the 10 
hypothalamus and the liver. Anat Rec A Discov Mol Cell Evol Biol 2004; 280: 808-20 11 
[41] Wick AN, Drury DR, Nakada HI, Wolfe JB. Localization of the primary 12 
metabolic block produced by 2-deoxyglucose. J Biol Chem 1957; 224: 963-9 13 
[42] Yamazaki H, Arai M, Matsumura S, Inoue K, Fushiki T. Intracranial 14 
administration of transforming growth factor-beta3 increases fat oxidation in rats. Am J 15 
Physiol Endocrinol Metab 2002; 283: E536-44 16 
[43] Yoshida G, Li MX, Horiuchi M, Nakagawa S, Sakata M, Kuchiiwa S, 17 
Kuchiiwa T, Jalil MA, Begum L, Lu YB, Iijima M, Hanada T, Nakazato M, Huang ZL, 18 
Eguchi N, Kobayashi K, Saheki T. Fasting-induced reduction in locomotor activity and 19 
reduced response of orexin neurons in carnitine-deficient mice. Neurosci Res 2006; 55: 20 
78-86 21 
[44] Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 22 
proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. 23 





Figure Legends 1 
Fig. 1.  Effect of intraperitoneal (i.p.) administration of energy metabolism inhibitors 2 
[mercaptoacetate (MA) and 2-deoxyglucose (2-DG)] on spontaneous motor activity 3 
(SMA).  SMA over 60 minutes was determined 2 h after i.p. administration of MA 4 
(400 µmol/kg B.W.; A and C) and 2-DG (400 mg/kg B.W.; B and D).  An identical 5 
volume of saline was administered to animals in the control group.  (A) and (B) show 6 
time course changes in SMA.  (C) and (D) show cumulative SMA values from 0 to 60 7 
min.  Values are mean ± S.E.M. (n = 13-14).  (***, P < 0.001; **, P < 0.01 by Student’s 8 
t test) 9 
 10 
Fig. 2.  Effect of i.p. administration of energy metabolism inhibitors on transforming 11 
growth factor-beta (TGF-beta) levels in the cerebrospinal fluid (CSF). CSF was 12 
collected 2 h after i.p. administration of MA (400 µmol/kg B.W.; A) or 2-DG (400 13 
mg/kg B.W.; B).  An identical volume of saline was administered to animals in the 14 
control group.  The average relative luminescence units (RLU) value in the control 15 
group was defined as 100%.  Values are mean ± S.E.M. (n = 12-14).  (*, P < 0.05 by 16 
 31 
Student’s t-test) 1 
 2 
Fig. 3.  Effect of intracisternal (i.c.) administration of anti-TGF-beta or non-immune 3 
control antibodies (5 µg dissolved in 10 µL) on SMA after i.p. administration of energy 4 
metabolism inhibitors MA (400 µmol/kg B.W.; A) and 2-DG (400 mg/kg B.W.; B).  An 5 
identical volume of saline was administered i.p. to control animals.  SMA cumulative 6 
values over 1 h were determined 2 h after the i.c. and i.p. administrations.  Values are 7 
mean ± S.E.M. (n = 6-8).  (**, P < 0.01; *, P < 0.05 by two-way ANOVA, followed by 8 
one-way ANOVA and post-hoc Tukey's multiple comparison test (A) and two-way 9 
ANOVA followed by Student’s t test to identify which group differences accounted for 10 
the significant P value (B)) 11 
 12 
Fig. 4.  Effect of vagotomy on SMA after i.p. administration of the energy metabolism 13 
inhibitors MA (400 µmol/kg B.W.; A) and 2-DG (400 mg/kg B.W.; B).  An identical 14 
volume of saline was administered i.p. to control animals.  SMA cumulative values over 15 
1 h were determined 2 h after i.p. administration.  Values are mean ± S.E.M. (n = 7-8).  16 
 32 
(**, P < 0.01; *, P < 0.05 by one-way ANOVA, followed by a post-hoc Tukey's 1 
multiple comparison test.) 2 
 3 
Fig. 5.  Effect of vagotomy (A) and sham surgery (B) on TGF-beta levels in the CSF 2 h 4 
after i.p. administration of MA (400 µmol/kg B.W.).  An identical volume of saline was 5 
administered to animals in the control group.  The average RLU value in control groups 6 
was defined as 100%.  Values are mean ± S.E.M. (n = 12-14).  (*, P < 0.05 by Student’s 7 























































































































































































































































































































































Supplementary Figure 1. Effect of i.p. administration of etomoxior on TGF-beta level in 10 
the CSF. CSF was collected 2 h after i.p. administration of etomoxior (25 mg/kg B.W.) 11 
An identical volume of saline was administered to animals in the control group.  The 12 
average relative luminescence units (RLU) value in the control group was defined as 13 
100%.  Values are mean ± S.E.M. (n = 6-7).  (*, P < 0.05 by Student’s t-test) 14 
 15 
Materials & Methods 16 
Etomxior was purchased from Sigma Aldrich Japan (Tokyo, Japan). Etomoxir was 17 
dissolved in sterile saline (Otsuka Pharmaceutical, Tokyo, Japan). Saline was used as 18 
control. Other protocols are described in Materials & Methods section in article.  19 
